Patents by Inventor Gerold L. Mosher

Gerold L. Mosher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LISINOPRIL FORMULATIONS
    Publication number: 20210187055
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Application
    Filed: March 5, 2021
    Publication date: June 24, 2021
    Inventors: Gerold L. MOSHER, David W. MILES
  • AMLODIPINE FORMULATIONS
    Publication number: 20210186942
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Application
    Filed: March 5, 2021
    Publication date: June 24, 2021
    Inventors: Scott Brauer, Gerold L. Mosher
  • Enalapril formulations
    Patent number: 11040023
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: June 22, 2021
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • ENALAPRIL FORMULATIONS
    Publication number: 20210137882
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 13, 2021
    Inventors: Gerold L. Mosher, David W. Miles
  • Amlodipine formulations
    Patent number: 10959991
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: March 30, 2021
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Amlodipine formulations
    Patent number: 10952998
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: March 23, 2021
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Lisinopril formulations
    Patent number: 10940177
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 9, 2021
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • Enalapril formulations
    Patent number: 10918621
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: February 16, 2021
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • AMLJODIPINE FORMULATIONS
    Publication number: 20210023003
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Application
    Filed: October 9, 2020
    Publication date: January 28, 2021
    Inventors: Scott Brauer, Gerold L. Mosher
  • Amlodipine formulations
    Patent number: 10894039
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: January 19, 2021
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • ENALAPRIL FORMULATIONS
    Publication number: 20200368200
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Inventors: Gerold L. MOSHER, David W. MILES
  • AMLODIPINE FORMULATIONS
    Publication number: 20200338055
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Application
    Filed: July 13, 2020
    Publication date: October 29, 2020
    Inventors: Scott Brauer, Gerold L. Mosher
  • AMLODIPINE FORMULATIONS
    Publication number: 20200338054
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Application
    Filed: July 13, 2020
    Publication date: October 29, 2020
    Inventors: Scott Brauer, Gerold L. Mosher
  • Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
    Patent number: 10799599
    Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: October 13, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher
  • Amlodipine formulations
    Patent number: 10799453
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: October 13, 2020
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Enalapril formulations
    Patent number: 10799476
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: October 13, 2020
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Gerold L. Mosher, David W. Miles
  • Enalapril formulations
    Patent number: 10786482
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: September 29, 2020
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • Enalapril formulations
    Patent number: 10772868
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: September 15, 2020
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Gerold L. Mosher, David W. Miles
  • ENALAPRIL FORMULATIONS
    Publication number: 20200281893
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: May 26, 2020
    Publication date: September 10, 2020
    Inventors: Gerold L. MOSHER, David W. MILES
  • DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN
    Publication number: 20200276314
    Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
    Type: Application
    Filed: May 15, 2020
    Publication date: September 3, 2020
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker